U.S. markets open in 3 hours 7 minutes
  • S&P Futures

    4,449.25
    +3.50 (+0.08%)
     
  • Dow Futures

    34,776.00
    +102.00 (+0.29%)
     
  • Nasdaq Futures

    15,283.25
    -35.50 (-0.23%)
     
  • Russell 2000 Futures

    2,253.00
    +9.00 (+0.40%)
     
  • Crude Oil

    74.91
    +0.93 (+1.26%)
     
  • Gold

    1,747.40
    -4.30 (-0.25%)
     
  • Silver

    22.50
    +0.07 (+0.31%)
     
  • EUR/USD

    1.1703
    -0.0015 (-0.13%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    18.36
    -0.27 (-1.45%)
     
  • GBP/USD

    1.3694
    +0.0014 (+0.10%)
     
  • USD/JPY

    110.9400
    +0.2550 (+0.23%)
     
  • BTC-USD

    43,897.98
    +845.57 (+1.96%)
     
  • CMC Crypto 200

    1,094.83
    -8.23 (-0.75%)
     
  • FTSE 100

    7,067.87
    +16.39 (+0.23%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse ESG Forum Switzerland virtual event.

  • Ensovibep is currently being studied in Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, in collaboration with Novartis (EMPATHY); and a National Institutes of Health-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol.

  • Interim data from EMPATHY Phase 2/3 trial is expected in H2 2021, and complete topline data expected in early 2022.

  • ACTIV-3 study is enrolling, with topline data expected in 2022.

  • The management outlined the initiation of a subcutaneous program expected in 2H of 2021 to evaluate ensovibep delivered subcutaneously to healthy individuals and subsequently to COVID-19 patients.

  • The Company also shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.

  • In March 2021, the Company announced positive initial data from its Phase 1 study of ensovibep in healthy volunteers, which showed that ensovibep was safe and well-tolerated with a half-life of 2-3 weeks.

  • Price Action: MOLN shares are up 1.75% at $19.19, and NVS shares are down 0.09% at $92.02 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.